Collectively, these findings highlight curcumin as a potent multi-target agent that inhibits BCR-ABL signaling, modulates oncogenic pathways, and holds promises for overcoming resistance in CML treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.